Spanish Oncology has established a new standard treatment for Breast Cancer at early stages, thanks to the results of the study 9805/Target 0 funded by the Spanish Breast Cancer Research Group (GEICAM) and sponsored by Sanofi Aventis. More than a thousand patients and 50 hospitals participated in the study, whose findings are reported in the latest issue of The New England Journal of Medicine...
More...